Exact Therapeutics AS

Exact Therapeutics AS Debt/EBITDA

Total Debt to EBITDA Ratio of Exact Therapeutics AS (EXTX.OL) as of Oct 19, 2026.

Debt/EBITDA

-0.00

YoY

-92.60%

Last updated:

Total Debt to EBITDA Ratio of Exact Therapeutics AS is 2024 -0.00 . Total Debt to EBITDA Ratio of Exact Therapeutics AS was 2023 -0.01 . It decreases by -92.60% higher compared to the previous year.

The Exact Therapeutics AS Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.00 NOK
Jan 1, 2018
0.00 NOK
Jan 1, 2019
-0.00 NOK
Jan 1, 2020
0.00 NOK
Jan 1, 2021
-0.02 NOK
Jan 1, 2022
-0.03 NOK
Jan 1, 2023
-0.01 NOK
Jan 1, 2024
-0.00 NOK
The Exact Therapeutics AS Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.00-92.60%
-0.01-54.26%
-0.03+34.22%
-0.02—
0.00-100.00%
-0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Exact Therapeutics AS Stock analysis

What does Exact Therapeutics AS do? Exact Therapeutics AS is a clinical stage biopharmaceutical company headquartered in Oslo, Norway, specializing in biotechnology within the Health Care sector. The company focuses on developing a novel platform for ultrasound-mediated therapeutic amplification, specifically targeting drug enhancement through ACT sonoporation. This technology aims to amplify the clinical utility of various therapeutic agents across cancer, infectious diseases, and neurological conditions. Listed on 14 July 2020, Exact Therapeutics operates with a team of eight employees. Exact Therapeutics AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exact Therapeutics AS stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Exact Therapeutics AS since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Exact Therapeutics AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Exact Therapeutics AS

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Exact Therapeutics AS